Méhtestrák: vizsgálatok itt: Hollandia
22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Amsterdam, Maastricht, Zwolle
- Életkor
- 18 év and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00 - 3. fázisTaking peopleA Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Where
- Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00 - 3. fázisTaking peopleA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Where
- Maastricht, Utrecht
- Életkor
- 18 év and over
- People
- 1123 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 2. fázisTaking peoplePan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 153
- Run by
- Netherlands Cancer Institute
See details and how to joinNCT06279130 · EU 2023-505756-21-00 - 2. fázisTaking peopleAdjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Where
- Arnhem, Eindhoven, Leiden, Maastricht, Rotterdam, The Hague
- Életkor
- 18 év and over
- People
- 393 worldwide
- Run by
- Canadian Cancer Trials Group
See details and how to joinNCT05640999 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisTaking peopleDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00 - 3. fázisTaking peopleRefining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
- Where
- Amsterdam, Breda, Eindhoven, Enschede, Groningen, Leeuwarden, Leiden, Maastricht, Rotterdam, 's-Gravenhage, Tilburg, Utrecht
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Leiden University Medical Center
See details and how to joinNCT05255653 · EU 2023-503267-42-00 - 1/2. fázisTaking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Groningen, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - 1/2. fázisTaking peopleA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- Where
- Amsterdam, Utrecht
- Életkor
- 18 év and over
- People
- 47 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07213609 - 3. fázisTaking peoplePuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Where
- Amsterdam, Maastricht
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00 - No phaseTaking peopleIndividualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation
- Where
- Arnhem, Breda, Doetinchem, Ede, Eindhoven, Geldrop, Helmond, Nijmegen, 's-Hertogenbosch, Tilburg, Uden, Veldhoven, Winterswijk
- Életkor
- 45 év and over
- People
- 735
- Run by
- Radboud University Medical Center
See details and how to joinNCT07200466 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1/2. fázisTaking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Amsterdam, Rotterdam
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - 1. fázisTaking peopleA Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
- Where
- Amsterdam, Nijmegen
- Életkor
- 18 év and over
- People
- 21
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-516870-31-00 · EU 2024-516870-31-00 - No phaseNot yet taking people in HollandiaSerous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study
- Where
- Rotterdam
- Életkor
- 18 év and over
- People
- 100
- Run by
- Erasmus Medical Center
See details and how to joinNCT06677242 - 1/2. fázisTaking peoplePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 47
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT04014530 · EU 2023-509457-31-00 - No phaseTaking peoplePROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
- Where
- Nijmegen
- Életkor
- 18 év to 110 év
- People
- 150
- Run by
- Radboud University Medical Center
See details and how to joinNCT03621904 - 4. fázisTaking peopleBiomarker Guided Treatment in Gynaecological Cancer
- Where
- Nijmegen
- Életkor
- 18 év to 95 év
- People
- 1300 worldwide
- Run by
- Haukeland University Hospital
See details and how to joinNCT02543710